Catalog number: SBB-DE0026, 50 μg
Purified recombinant human Sentrin Specific Protease 1 (SENP1, catalytic domain) is a SUMO-specific enzyme that catalyzes two essential functions. Processing the full-length versions of SUMO1, SUMO2, and SUMO3 into its mature forms and the deconjugation of SUMOylated proteins. This SENP1 is N-terminally His6 tagged and expressed in E.coli.[1][2][3][4]
His6-SENP1, human recombinant
SUMO/Sentrin Specific Peptidase 1 (SENP1) is a member of the SENP family of proteases, which belong to the group of cysteinetype peptidases that either catalyze the mature form of full-length Small Ubiquitinrelated MOdifiers (SUMOs), or the deconjugation of SUMOs from SUMOylated proteins, specifically SUMO2/3 chains by removing the distal SUMO1. SENP1 is expressed in many organs and is localized in the nucleus as well as the cytoplasm. SENP1 is thought to play a role in the development, progression, and metastasis of prostate cancer and has been shown to regulate erythropoietin production during hypoxia by regulating the stability of HIF1α. Furthermore, SENP1 deconjugates SUMO1 from HIPK2, from HDAC1, and BHLHE40/DEC1, which decreases its transcriptional repression activity. SENP1 has been shown to desumoylate CCAR2, which subsequently decreases the interaction with SIRT1.